Home > Oncology > ASCO GU 2022 > Urothelial Carcinoma > Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma

Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma

Presented By
Dr Wesley Yip, Memorial Sloan Kettering Cancer Center, NY, USA
Conference
ASCO GU 2022
Trial
Phase 2
In a phase 2 trial, neoadjuvant chemotherapy with gemcitabine plus cisplatin had a favourable pathologic response rate in patients with high-risk upper tract urothelial carcinoma. Upper tract urothelial carcinoma is a rare but deadly disease; 5-year cancer-specific mortality rates for T2–T4 disease ranges from 21% to 59%. Irrespective of stage, patients with high-grade disease have a significantly worse prognosis [1]. Previously, the POUT trial (NCT01993979) demonstrated that adjuvant gemcitabine-platinum chemotherapy improves disease-free survival in patients with advanced upper tract urothelial carcinoma [2]. In addition, neoadjuvant chemotherapy has proven survival benefits for invasive urothelial carcinoma of the bladder, yet its role in upper tract urothelial carcinoma remains undefined. The current multicentre, prospective, single-arm, phase 2 study (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on